跳至主要内容
临床试验/CTRI/2020/06/026240
CTRI/2020/06/026240招募中未知

To Study the Effects of Addition of Mebendazole to Lenvatinib in Cirrhotics With Advanced Hepatocellular Carcinoma.

Institute of Liver and Biliary Sciences0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
招募中

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1) Cirrhosis of Liver with HCC on imaging and/or biopsy or cytology
  • 2) Child Pugh A, Child Pugh B < 8
  • 3) Advanced HCC - as defined by BCLC - C
  • 4) ECOG Performance Status 1-2
  • 5) Adequately controlled blood pressure (BP) with up to 3 antihypertensive agents, defined as BP <=150/90 millimeters of mercury (mmHg) at screening and no change in antihypertensive therapy within 1 week prior to commencement of intervention.
  • 6) Valid Consent
  • 7) Age 18-70 years

排除标准

  • 1) Decompensated Cirrhosis
  • 2) Child Pugh C, Child Pugh B > 7
  • 3) HCC patients with a curative therapy (RFA/MWA or LT)
  • 4) Prior systemic therapies (or) immunotherapy for HCC
  • 5) ECOG Performance Status 3-4
  • 6) Post Liver transplant HCC recurrence
  • 7) Pregnancy

研究者

相似试验

Effects of Mebendazole to Lenvatinib (drug) in liver... | 临床试验